Pneumococcal vaccine: Key market research findings
- The Americas dominate the market geographically
- PCV accounts for a majority share of the market’s revenue
- Key vendors – Pfizer, Sanofi, GSK, and Merck
Technavio’s market research analysts predict the global pneumococcal vaccine market to grow at a CAGR of more than 8% between 2016 and 2020. The growth of this market can be attributed to the global action plan for pneumococcal vaccines. The plan was intended to combat the global shortage of the vaccine. It is a comprehensive strategy that focuses on increasing the use of the vaccine, and expanding its production capacity and R&D. During 2015, the global market for pneumococcal vaccine was dominated by the Americas with a market share of around 45%. The higher incidences of pneumococcal infections in the US has resulted in the growing consumption of pneumococcal vaccine, which in turn, will drive the growth of the market in this region during the forecast period.
The new market research report from Technavio presents a breakdown and analysis of the pneumococcal vaccine segments based on the composition.
“The emergence of protein-based combination pneumococcal vaccines is an upcoming trend in the market. There is an increasing number of new pneumococcal protein-based vaccines, which are undergoing clinical trial evaluations. These protein-based vaccines consist of serotype-independent subunit vaccines containing purified proteins and antigens that are expressed by recombinant bacteria,” says Barath Palada, Lead Analyst, Healthcare & Lifesciences, Technavio Research.
During 2015, the PCV segment accounted for around 85% of the overall market share to become the dominant generator in the global pneumococcal vaccine market. Conjugate vaccines contain an immunogenic non-pneumococcal protein conjugated to individual pneumococcal polysaccharides. Currently, there are three conjugate vaccines available to immunize individuals in the global pneumococcal conjugate vaccine market. Synflorix is a decavalent conjugate vaccine, which contains ten serotypes of the pneumococcal vaccines conjugated to a carrier protein.
The key vendors in the market include Pfizer, Sanofi, GSK, and Merck. The global pneumococcal vaccine market is competitive and is dominated by Pfizer. In this market, Pfizer dominates over the other vendors in terms of shares due to its robust vaccine product, Prevnar, which generated revenues of over USD 6 billion in 2015.
A more detailed analysis is available in the Technavio report, Global Pneumococcal Vaccine Market 2016-2020.
We can customize reports by other regions and specific segments upon request.
Other related reports:
